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Group 2 innate lymphoid cells (ILC2s) are recently identiﬁed cell populations that produce type 2 cy-
tokines such as IL-5 and IL-13 in response to epithelial cell-derived cytokines. Although ILC2s were
initially reported to play a key role in the anti-helminth innate immunity, we now have greater interest
in their role in asthma and other allergic diseases. In various asthma mouse models, ILC2s provoke
eosinophilic inﬂammation accompanied by airway hyperresponsiveness independent of acquired im-
munity. Moreover, recent mouse studies show that ILC2s also promote acquired immunity and Th2
polarization, and various cytokines and lipid mediators inﬂuence the functions of ILC2s. Although ILC2s
have also been identiﬁed in humans, studies on the role of human ILC2s in asthma are very limited. Thus
far, human studies have shown that there is a slight difference in responsiveness and production of
cytokines between mouse and human ILC2s, and it has been suggested that ILC2s are involved in allergic-
type asthma and the exacerbation of asthma. In this review, we focus on mouse and human ILC2s, and
discuss their role in asthma.
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Asthma is an airway disease characterized by bronchial hyper-
responsiveness, reversible airﬂow limitation, and airway inﬂam-
mation. Classically, acquired immunity and antigen-speciﬁc Th2
cells, which secrete type 2 cytokines such as IL-4, IL-5, and IL-13,
have been considered to play pivotal roles in the pathogenesis of
asthma.1 IL-5 induces development, recruitment, and activation of
eosinophils,2 whereas IL-13 promotes hyperproduction of mucus
and airway remodeling.3 Hence, antibodies against these cytokines
are expected as a new treatment of asthma.4
Innate immunity, which refers to a nonspeciﬁc defense mech-
anism against numerous pathogenic microbes, provides immediate
recognition and response to pathogens. Relatively little was known
about the role of innate immunity in the pathology of asthma until
the recent discovery of innate lymphoid cells that produce large
amounts of type 2 cytokines upon stimulation by epithelial cell-
derived cytokines, now termed group 2 innate lymphoid cells
(ILC2s).5e8 Mouse studies have suggested that ILC2s are major
sources of IL-5 and IL-13, and that ILC2s might have a role in the
pathophysiology of asthma.9 However, studies of the role of human
ILC2s in asthma are currently very limited; moreover, there are
slight differences between mouse and human ILC2s. In this review,
we will review the characteristics of mouse and human ILC2s, and
discuss their role in asthma.
Discovery of ILC2
In 2010, groundbreaking studies from three independent re-
searchers reported the identiﬁcation of cell populations involved in
type 2 innate immunity. Moro et al. were the ﬁrst to identify the fat-
associated lymphoid cluster (FALC), a previously unrecognized
lymphoid structure in mouse and human mesenteric adipose tis-
sue.5 In addition, they noted a novel cell population in FALC, and
named them natural helper (NH) cells. NH cells produce large
amounts of IL-5 and IL-13 in response to IL-33 or a combination of
IL-2 and IL-25, and they express Sca-1, c-Kit, IL-33 receptor, IL-2
receptor, Thy1, and IL-7 receptor, but lineage markers (CD3, CD4,
CD5, CD8, CD19, B220, NK1.1, Gr-1, FcεRIa, CD11b, CD11c, TER119)
are not expressed. Following this report, Neill et al. reported that IL-
25 or IL-33 administered to IL-13 reporter mice led to the accu-
mulation of a lineage-negative IL-13-positive population, named
nuocytes, in the mesenteric lymph nodes, spleen, and bone
marrow.6 Similarly, Price et al. identiﬁed a population of lineage-
negative IL-13-positive cells, which were named innate helper
type 2 (Ih2) cells,7 using IL-4 or IL-13 reporter mice. All of these
lymphoid cells have no antigen-speciﬁc receptors and cause
nonspeciﬁc immune responses, as well as natural killer cells and
lymphoid tissue-inducer cells. Hence, these cells were collectively
termed innate lymphoid cells.
In 2013, the classiﬁcation of innate lymphoid cells was proposed
on the basis of their phenotypical and functional characteristics,
and innate lymphoid cells were classiﬁed into three groups: Group
1 (producing IFN-g), Group 2 (producing IL-5 and IL-13), and Group
3 (producing IL-17 and/or IL-22).8 NH cells, nuocytes, and Ih2 cells
are able to produce IL-5 and IL-13 in response to IL-25 or IL-33;
these cells depend on the transcription factors GATA3 and RORa
for their development and function.10e15 Therefore, they are all
classiﬁed as ILC2s by virtue of these common features.
Characteristics of mouse ILC2
As mentioned above, the most notable feature of ILC2s is their
ability to secrete IL-5 and IL-13 in response to epithelial cell-
derived cytokines such as IL-33 and IL-25. These epithelial cell-derived cytokines are released from epithelial cells, endothelial
cells, and other immune cells during cellular damage or allergen
exposure.16 However, the responsiveness to these cytokines differs
depending on the ILC2 subset. NH cells proliferated and produced
large amounts of IL-5 and IL-13 when they were cultured in the
presence of IL-33 or a combination of IL-2þIL-25 in vitro.5 Sur-
prisingly, NH cells produced ～1 pg/cell of IL-5 and IL-13 after
stimulation with IL-33 for 96 h12 On the other hand, nuocytes
isolated from spleens of IL-25-administered mice did not prolifer-
ate when they were cultured with IL-25 or IL-33 alone, whereas
nuocytes proliferated robustly in a combination of IL-33 and IL-7.6
In addition, differences in cell-surface markers have been noted
among NH cells, nuocytes, and Ih2 cells (Table 1). Therefore, it has
been considered that distinct cell subsets might be present in a
population of ILC2s, or some ILC2s might have phenotype plas-
ticity.17 In fact, IL-25-responsive ILC2s, expressing large amounts of
KLRG1 and IL-25 receptor but not IL-33 receptor, have recently been
discovered.18 This cell populationwas named “inﬂammatory ILC2s”
(iILC2s), and appeared in lung, spleen, and mediastinal lymph
nodes at early time points after IL-25 administration or helminth
infection. Further investigation revealed that iILC2s quickly ac-
quired the expression of the IL-33 receptor and responsiveness to
IL-33 in vitro and in vivo. Therefore, this ﬁnding conﬁrmed that
ILC2s might change their phenotype, including their expression of
cell surface markers and responsiveness to cytokines.
Furthermore, ILC2s were identiﬁed in many organs and tissues
(lung, skin, brain, heart, intestine, and liver),19 and their respon-
siveness to cytokines slightly differed depending on the tissue. In
lungs, the IL-33 receptor expression of lung ILC2s was lower than
that of NH cells,20e22 and there was a synergistic effect on the
proliferation or production of type 2 cytokines when lung ILC2s
were cultured with a combination of IL-33 and STAT5 activators
such as IL-2, IL-7 or thymic stromal lymphopoietin (TSLP)
compared to IL-33 alone.20e22 In addition, it was recently reported
that IL-4 also enhanced the responsiveness to IL-33 in lung ILC2s.23
ILC2s have been shown to be activated by some other cytokines
or lipid mediators. TL1A (TNFSF15) belongs to the tumor necrosis
factor (TNF) family of cytokines and it is produced by activated
myeloid cells and stressed epithelial and endothelial cells.24
Although TL1A is known to regulate acquired immune responses
in the gut and lungs, recent studies have shown that TL1A is able to
directly stimulate ILC2s to produce type 2 cytokines independent of
IL-25 or IL-33.25,26 As for lipid mediators, ILC2s express cysteinyl
leukotriene receptor 1 (CysLT1R), the high-afﬁnity receptor for
leukotriene D4 (LTD4).27 Cysteinyl leukotrienes are generated by
mast cells, eosinophils, macrophages, and dendritic cells, and cause
contractions of smooth muscle cells and inﬂammation in asthma
and allergic rhinitis.28 LTD4 induces the production of IL-5 and IL-13
from lung ILC2s in a CysLT1R-dependent manner. Intriguingly,
although IL-33 or IL-25 stimulation does not induce IL-4 production
from ILC2s, LTD4 induces IL-4 production from ILC2s.27 IL-4 is an
important cytokine leading to Th2 cell polarization and class
switching of the immunoglobulins synthesized by B cells.29 This
ﬁnding suggests that ILC2s possibly promote acquired immune
responses as well as innate immune responses. Likewise, some
ILC2s also express OX40L and MHC class II,30e32 and are able to
activate CD4 T cells. Furthermore, IL-13 produced by ILC2s pro-
motes dendritic cell migration to the draining lymph nodes to
stimulate Th2 polarization.33
Finally, mouse ILC2s produce not only IL-5 and IL-13, but also IL-
6, IL-9, and amphiregulin. NH cells produce IL-6, which promotes
IgA production in combination with IL-5.5 In the presence of IL-2,
lung ILC2s produce IL-9, a pleiotropic cytokine that contributes to
mast cell accumulation, airway eosinophilia, and mucus produc-
tion.34 IL-9 also acts as an autocrine factor that promotes the
Table 1
Characteristics of mouse and human ILC2s.
NH cell5 Nuocyte6 Ih2 cell7 iILC218 Lung ILC220e22 Human ILC240
Distribution
FALC Mesenteric LNs Mesenteric LNs Mesenteric LNs Lung Gut(fetal)
Spleen Spleen Spleen Lung(fetal, adult)
Bone marrow Liver Liver Blood(adult)
Bone marrow Lung Nasal polyp
Lung BALF
Cell surface antigens
Lineage () () () () () ()
c-Kit (þ) (þ)/() (þ) (þ) (þ)/low (þ)/()
Sca-1 (þ) (þ) () () (þ) ?
CD45 (þ) (þ) (þ) ? (þ) (þ)
IL-7R (CD127) (þ) low ? low (þ) (þ)
Thy-1 (CD90) (þ) (þ) (þ) low (þ) ?
CD34 () () ? ? ()z ?
IL-2R (CD25) (þ) ? ? ? (þ) (þ)
CD44 (þ) (þ) ? (þ) (þ) ?
CD69 (þ) ? ? ? (þ)z ?
IL-33R (T1/ST2) (þ) (þ)/() ? () (þ)z (þ)
MHC class 2 () (þ) ? ? (þ)/()z ?
IL-25R (IL-17RB) ? (þ) ? (þ) ()z (þ)
Others ICOS KLRG1 high ICOSz CD161
CRTH2
Transcription factors
GATA3 GATA3 GATA3 GATA3
RORa RORa
Responsiveness to IL-25 or IL-33
IL-25 (in vitro) B(þIL-2)  ? By  B(þIL-2)
IL-33 (in vitro) B B(þIL-7) ? By △～B B(þIL-2)
IL-25 (in vivo) B(þIL-2) B B B △～ ?
IL-33 (in vivo) B B B  B ?
NH, natural helper; Ih2, innate helper type 2; iILC2, inﬂammatory ILC2; FALC, fat-associated lymphoid cluster; LN, lymph node; BALF, bronchoalveoar ﬂuid; ICOS, inducible T
cell co-stimulator; KLRG1, killer cell lectin-like receptor G1; CRTH2, chemoattractant receptor-homologousmolecule on Th2 cells; GATA3, GATA binding protein 3; RORa, RAR-
related orphan receptor a.
y After 3 days of culture in the presence of IL-2þIL-7þIL-25.
z The expression of receptors varies depending on the study.
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protein BCL3.35,36 Furthermore, ILC2s can produce the EGF recep-
tor ligand amphiregulin, which is involved in the repair of damaged
epithelial barriers following acute infection with inﬂuenza virus.37
Amphiregulin also induces mucous production in bronchial
epithelial cells, and its level in the sputum of asthmatic patients
was increased and correlated with the number of eosinophils in the
sputum.38,39 Therefore, ILC2s might contribute to promoting
remodeling via the production of amphiregulin in asthma (Fig. 1).Characteristics of human ILC2
In 2011, Mj€osberg et al. identiﬁed lineage-negative cells
expressing the IL-7 receptor, CD161, and CRTH2 in fetal gut and
lung, adult lung, peripheral blood, and nasal polyps of chronic
rhinosinusitis in humans.40 These cells produce IL-13 in response to
a combination of IL-2þIL-25 or IL-2þIL-33, andwere named human
ILC2s. Compared to mouse ILC2s, the ability of human ILC2s to
produce type 2 cytokines is modest in response to IL-33 alone, and
a combination of IL-2þIL-25 or IL-2þIL-33 is necessary to assess the
cytokine production of human ILC2s in vitro. Furthermore, human
ILC2s stimulated with these combinations of cytokines produce not
only IL-5 and IL-13, but also IL-4 and other cytokines such as GM-
CSF, IL-6, IL-8, IL-9, and IP-10. Human ILC2s express CRTH2, a re-
ceptor for prostaglandin D2 (PGD2), a lipid mediator that is released
from activated mast cells and is associated with the severity of
asthma.41 It has been reported that innate lymphoid cells are
located near mast cells in small and medium airways of human
lung. PGD2 induces themigration of human ILC2s, upregulates their
expression of IL-33 and IL-25 receptors, and induces the secretionof IL-3, IL-4, IL-5, IL-8, IL-9, IL-13, IL-21, GM-CSF, and CSF-1 from
human ILC2s.42,43 Similar to mouse ILC2s, TL1A induces human
ILC2s to produce type 2 cytokines. Mouse studies have shown that
GATA3 is an essential transcription factor for developing and pro-
ducing type 2 cytokines in mouse ILC2s,10e12 and GATA3 has a
pivotal role in human ILC2s. TSLP stimulates phosphorylation of
STAT5 and enhances GATA3 expression, and has a synergistic effect
with IL-2þIL-33 on the production of cytokines such as IL-4, IL-5,
and IL-13.44 Human ILC2s express Lipoxin A4 receptor (ALX/formyl
peptide receptor 2 (FPR2)) and lipoxin A4 decreases the production
of IL-13 in human ILC2s45 (Fig. 2).ILC2 and asthma in mice
Although asthma has long been considered a disease associated
with Th2 cells and acquired immunity, type 2 cytokines produced
by ILC2s are now suggested to play an important role in asthma.46
The administration of IL-33 or IL-25 into mice induces airway
hyperresponsiveness and goblet cell hyperplasia accompaniedwith
increased eosinophil counts and type 2 cytokines independent of
acquired immunity.47e49 IL-33 is more potent than IL-25 in acti-
vating lung ILC2s and airway contraction,50 whereas IL-25 also
activates other cell populations that produce type 2 cytokines such
as type 2 myeloid cells and MPP type 2 cells.51,52 Further studies
have revealed that these epithelial cell-derived cytokines directly
activate lung ILC2s, and type 2 cytokines produced by lung ILC2s
induce an asthma-like phenotype in the airways.20e22 Therefore, it
has been proposed that the allergic response involving ILC2s should
be referred to as “innate-type allergy”, as opposed to the “acquired-
type allergy” associated with T cells.53 Many asthma-related
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Fig. 1. Network of cytokines and lipid mediators in representative mouse ILC2s. IL-33, IL-25, TL1A (TNF-like ligand 1A), or LTD4 (leukotriene D4) induces the secretion of IL-5, IL-13,
IL-9, and AREG (amphiregulin) from ILC2s. LTD4 also induces IL-4. These cytokines play different roles in asthma pathology. Addition of STAT5-activating cytokines such as IL-2, IL-7,
and TSLP (thymic stromal lymphopoietin) to epithelial cell-derived cytokines enhances the proliferation and cytokine production of ILC2s. IL-9, which is produced by ILC2s, en-
hances the survival of ILC2s. OX40L, MHC class II, IL-4, and IL-13 have been suggested to promote Th2 polarization.
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there are many reports demonstrating a mouse asthma model that
is caused by an “innate-type allergy” (Table 2). The administration
of fungus extracts (Alternaria alternata),21,27,54 protease
(papain),20,23,35 house dust mites,55 inﬂuenza virus,37,56,57 and a-
GalCel58 into the airways of mice induced the accumulation of ILC2s
via the induction of epithelial cell-derived cytokines such as IL-25
and IL-33, and led to airway hyperresponsiveness and mucus
overexpression independently of acquired immunity. These studies
focused on the initiation of the immune response in short-term
models. The house dust mite is one of the most common indoor
allergens, whereas Alternaria is a major fungal aeroallergen
worldwide. Exposure to Alternaria is associated with acute exac-
erbations of asthma.59 Papain is a plant-derived protease used in
food industry, and is recognized as a cause of occupational
asthma.60 Although IL-33 is released from the nuclei of damaged
and necrotic cells, exposure to Alternaria and some allergens in-
duces extracellular accumulation of ATP or uric acid, which induce
the release of IL-33 in an autocrine manner without cell necro-
sis.61,62 These ﬁndings indicate that ILC2s are implicated in asthma
exacerbation and occupational asthma in humans.
ILC2s have recently been implicated in acquired immunity. An
acquired immunity-mediated asthma model generated by sensiti-
zation and exposure to antigen such as papain or house dust mites
can be suppressed in RORa-deﬁcient mice that lack ILC2s, and it can
be reversed by adoptive transfer of ILC2s.33,63 Hence, ILC2s promote
acquired immune responses as well as innate immune responses
in vivo. On the other hand, results with the most popular asthma
mouse model, which is induced by ovalbumin (OVA) sensitization
and exposure, are controversial. In OVA-induced asthmatic mice,some studies showed that ILC2s were the major sources of IL-5 and
IL-13,48,54 but ILC2s were hardly induced in OVA-induced asthmatic
mice in our study,22 and another group showed that the accumu-
lation of eosinophils and type 2 cytokines was not signiﬁcantly
different between wild-type mice and RORa-deﬁcient mice.63
Therefore, the contribution of ILC2s to asthma models generated
via acquired immunity may differ depending on the type of antigen
or sensitization protocol. Recently, chronic asthma models induced
by administration of 3 representative allergens (house dust mite,
ragweed, and Aspergillus species) for 6 weeks were reported, in
which airway hyperreactivity persists for longer than 6 months
after cessation of allergen exposure.64 IL-33 and ILC2s were
involved in this persistence of airway hyperreactivity, and IL-13
produced by ILC2s induced the expression of IL-33 in epithelial
cells. Therefore, this feedback loop was suggested to be involved in
developing chronic asthma.
Viral infection and allergen exposure cause the exacerbation of
asthma. In such situations, innate immune responses might further
exacerbate the inﬂammation induced by acquired immunity. When
a low dose of IL-33 was administered to OVA-induced asthmatic
mice, eosinophilic inﬂammation was induced and this inﬂamma-
tion was resistant to corticosteroid treatment.22 Intriguingly,
although both Th2 cells and ILC2s were sources of type 2 cytokines
in these mice, corticosteroid only suppressed Th2 cells and failed to
suppress ILC2s. However, when IL-33 alone was administered to
naïve mice, corticosteroid completely suppressed ILC2s. Further
study showed that TSLP induced in OVA-induced asthmatic mice
plays a pivotal role in the induction of corticosteroid resistance in
ILC2s. These ﬁndings suggest that ILC2s might change corticoste-
roid sensitivity depending on the local inﬂammation milieu, and
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Fig. 2. Network of cytokines and lipid mediators in human ILC2s. IL-33, IL-25, TL1A (TNF-like ligand 1A), and PGD2 (prostaglandin D2) induce various cytokines including IL-4, IL-5,
IL-9, and IL-13. In vitro, stimulation with a combination of IL-2þ IL-33 or IL-2þIL-25 is necessary to assess the production of these cytokines. PGD2 also induces IL-3, IL-21, and CSF-1
(colony stimulating factor 1). TSLP (thymic stromal lymphopoietin) induces phosphorylation of STAT5 and activates GATA3 expression, and enhances ILC2 responsiveness to
stimulatory cytokines. Lipoxin A4 has a suppressive effect on ILC2s.
Table 2
Asthma mouse models associated with ILC2s.
Acute model (innate immunity)
Protease: Papain,20,23,35 Alternaria alternata,21,27,54 House dust mite,55
Virus infection: Inﬂuenza virus37,56,57
Others: a-GalCer58
Chronic model (Acquired immunity ± Innate immunity)
Protease: Papain,33 House dust mite,63 multiallergens64
Others: OVA ± IL-3322,49,55,63
a-GalCel, a-galactosylceramide; OVA, ovalbumin.
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asthma exacerbation.ILC2 and asthma in humans
In humans, many studies have implicated epithelial cell-derived
cytokines in asthma. For example, genome-wide association
studies have shown that genetic polymorphisms near the TSLP, IL-
33, and IL1RL1 loci are strongly linked to asthma.65e67 In addition,
the expression of TSLP and IL-33 is increased in the airways of
asthmatic patients,68,69 especially those with severe asthma.70e73
Furthermore, in pediatric patients with severe asthma, the
expression of IL-33 was not suppressed by corticosteroid treat-
ment.74 In recent years, asthma has been shown to be a heteroge-
neous disease composed of distinct phenotypes, such as early-
onset atopic, late-onset non-atopic, and obese-female types.75
Intriguingly, the expression of IL-25 was increased only in asubgroup of subjects with asthma, and this IL-25-high subgroup
displayed a Th2-high phenotype with evidence of eosinophil acti-
vation, increased expression of IL-13 pathway biomarkers, and
greater methacholine bronchoreactivity.76 IL1RL1, an IL-33 receptor
subunit, has also been shown to be associated with Th2-like
inﬂammation and severe asthma.77 Therefore, these ﬁndings sug-
gest that ILC2s are relevant to asthma, especially severe and Th2
phenotype asthmas.
On the other hand, reports concerning ILC2s in asthmatic pa-
tients are relatively rare at this point. One study has shown that
peripheral bloodmononuclear cells (PBMCs) produce IL-5 and IL-13
when they are stimulated by a combination of IL-2þIL-25 or IL-
2þIL-33, and this production is signiﬁcantly increased in patients
with allergic asthma compared to healthy controls or patients with
allergic rhinitis.78 This study also revealed that ILC2s in peripheral
blood were the major source of type 2 cytokines, and the total
number of ILC2s in peripheral blood was increased in subjects with
allergic asthma. As ILC2s in peripheral blood consist of a very small
fraction (approximately 0.01e0.03% of PBMCs), it might be difﬁcult
to compare the number of ILC2s using peripheral blood. In fact,
another study identiﬁed CRTH2-positive ILCs as ILC2s in peripheral
blood, and the proportion of these cells in CD127-positive ILCs was
not different between healthy control, mild asthmatics, and severe
asthmatics.45
ILC2s are present in the lungs and bronchoalveolar lavage (BAL)
ﬂuid in humans.37,45 Prior to the characterization of ILC2s, it was
reported that a CD34-positive non-B/non-T lymphocyte population,
expressing receptors for IL-33 and TSLP, produces IL-5 and IL-13 in
sputum of asthmatic patients, and the cell number increased after
Table 3
Identiﬁcation of ILC2s in patients with asthma.
Sample Identiﬁcation of ILC2s Findings Ref
Blood LinCRTH2þ cells The ratio of ILC2s was not different between control, mild, and severe asthmatics. 45
Blood LinIL-7R þ CRTH2þ cells The number of ILC2s was increased in subjects with allergic asthma. 78
Sputum CD34þIL-33R þ TSLPR þ non-T/B cells The number of ILC2s was increased after airway challenge with allergen. 79
BALF LinIL-7R þ FceRIIL-33R þ cells The frequency of ILC2s was increased in asthma compared to disease control subjects. 64
BALF, bronchoalveolar ﬂuid; CRTH2, chemoattractant receptor-homologous molecule on Th2 cells;TSLPR, thymic stromal lymphopoietin receptor.
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IL-33 levels and the number of ILC2s in BAL ﬂuid are increased in
asthmatic patients compared to disease-control subjects, and IL-33
levels are inversely correlated with lung function and asthma-
control test scores.64
Rhinovirus infection is known as a leading cause of the exac-
erbation of asthma, and it induces the expression of IL-33 and IL-25
in patients with asthma.80,81 A recent study revealed that rhino-
virus infection induces the expression of IL-33 in nasal tissue, and
the concentration of IL-33 correlated with the production of type 2
cytokines and symptoms in asthmatic patients.80 In addition, the
supernatants of rhinovirus-infected human bronchial epithelial
cells induce a higher level of type 2 cytokines such as IL-4, IL-5, and
IL-13 secreted from human ILC2s compared to those from CD4-
positive T cells, and this cytokine production was inhibited by
blocking the IL-33 pathway.
Thus far, the results of these studies have been consistent with
those of mouse studies, and they have demonstrated a relationship
between ILC2s and asthma, especially allergic-type asthma, severe
asthma, and virally induced exacerbation (Table 3). Although
mouse ILC2s were shown in the initial report to produce IL-5 and
IL-13, but not IL-4, it was subsequently shown that mouse and
human ILC2s are able to produce IL-4 and might promote Th2 po-
larization. Therefore, the relationship between ILC2s and non-
atopic asthma has remained unclear. An obese-female asthma
phenotype is one of the non-atopic phenotypes, and IL-17-
producing ILC3s facilitate obesity-associated airway hyperreactiv-
ity.82 On the other hand, ILC2s have an important role in regulating
metabolic homeostasis, and have been shown to be decreased in
obese patients.83 Therefore, ILC3s, not ILC2s, may contribute to an
obese-female and non-atopic phenotype of asthma.
Conclusion
ILC2s promote both innate and acquired immunity, and they are
associated with a variety of asthma mouse models. In recent years,
the details of ILC2 function have become increasingly clear. For
example, some cytokines and lipid mediators have been shown to
regulate ILC2s. However, in humans, although ILC2s have been
identiﬁed in some tissues, the relationship between ILC2s and the
pathology of asthma remains obscure. Future studies are needed to
clarify the inﬂuence of ILC2s in patients with asthma compared to
other types of cells, and determine which phenotypes involve
ILC2s.
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